Relief Advance 12 suppositories

Form

supozitoria

Pack

12

RELIEF® ADVANCE Rectal Suppositories International Nonproprietary Name Benzocaine. Trade Name RELIEF ADVANCE Dosage Form Rectal Suppositories Description Opaque, white to pale yellow, torpedo-shaped suppositories. Composition Active Substance (1 suppository contains): Benzocaine 206mg. Excipients: Cocoa butter, corn starch, methylparahydroxybenzoate (E218), propylparahydroxybenzoate (E216). Pharmacotherapeutic Group Medications for external use for hemorrhoids and anal fissures. Local anesthetics, ATC code: C05AD03 See blog: Relief - Hemorrhoid Ointment and Suppositories Pharmacological Properties Benzocaine exhibits local analgesic action. Indications Symptomatic treatment in complex therapy of hemorrhoids and anal fissures. Method of Administration and Dosage The preparation is used after hygienic procedures. Insert one suppository into the rectum up to 4 times a day (in the morning, before bedtime, and after each bowel movement). Duration of treatment is determined by the doctor, taking into account the characteristics of the disease, tolerability of the preparation, and achieved effects. Side Effects The following side reactions may develop: contact dermatitis, allergic skin reactions (hyperemia, rash, itching), local reactions at the site of application. Use of the preparation may cause methemoglobinemia (with cyanosis of the skin, lips and fingertips, headache, dizziness, respiratory distress, general weakness, tachycardia). If side reactions occur that are not described here, discontinue use of the preparation and consult a doctor. Contraindications Individual hypersensitivity to the ingredients of the preparation, as well as to other amide-type anesthetics, thromboembolism (including history of), granulocytopenia. Overdose In cases of significant overdose of recommended single and daily doses, a tendency towards hypercoagulation is observed. With overdose of benzocaine during systemic absorption, the following disorders may occur: drowsiness, restlessness, agitation, in severe cases - convulsions. Treatment is symptomatic. Cases of methemoglobinemia (with cyanosis of the skin, lips and fingertips, headache, dizziness, respiratory distress, general weakness, tachycardia) have been reported with benzocaine-containing preparations, which can be fatal, and therefore urgent medical assistance is required. Seek the emergency department of the hospital immediately upon the appearance of the above-mentioned symptoms. Precautions Patients with arterial hypertension, heart rhythm disturbances, hyperthyroidism, urinary excretion disorders (e.g., benign prostatic hyperplasia) should use the preparation after consulting a doctor. It is necessary to use the minimum dose of the preparation to achieve the desired effect. In case of significant bloody discharge from the rectum during the use of the preparation, or absence of therapeutic effect, consult a doctor. Cases of methemoglobinemia (with cyanosis of the skin, lips and fingertips, headache, dizziness, respiratory distress, general weakness, tachycardia) have been reported with benzocaine-containing preparations, which can be fatal, and therefore urgent medical assistance is required. High-risk groups for the development of methemoglobinemia include: young children, the elderly, patients with genetic disorders (glucose-6-phosphate dehydrogenase deficiency, pyruvate kinase deficiency, NADH-methemoglobin reductase (diaphorase 1) deficiency, M-hemoglobinopathy), patients with cardiovascular diseases, patients with respiratory diseases (bronchial asthma, bronchitis, pulmonary emphysema) or smokers. Due to the content of methylparahydroxybenzoate and propylparahydroxybenzoate, allergic reactions, including delayed type, may develop. Interaction with Other Medicines The preparation is not used concurrently with MAO inhibitors, antidepressants, and hypotensive drugs. Use in Children Use of the medicinal product is not recommended in children under 12 years of age. Pregnancy and Lactation Use of the medicinal product is not recommended during pregnancy and lactation. Effect on Driving and Operating Machinery There is no data on the effect of the preparation on driving and operating other machinery. Storage Conditions At a temperature not exceeding 25°C, in a place inaccessible to children. Shelf Life 2 years. Do not use after the expiry date indicated on the packaging. Packaging 6 suppositories in 2 strips, along with a leaflet, are placed in a cardboard box. Dispensing Conditions Over-the-counter.